SOLTI-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)
Eva Ciruelos1, Tomás Pascual2, Nuria Chic3, Montserrat Muñoz2, Begoña Bermejo4, Juan Antonio Virizuela5, Mafalda Oliveira6, Silvia Vázquez7, Salvador Blanch8, Laia Paré9, Fernando Salvador9, Patricia Villagrasa9 and Aleix Prat10
Communication in congress
ePoster
SABCS
2020
